Page 195 - 2021_06-Haematologica-web

MDS progression involves cohesin and RAS mutations
replication fork progression creates a tar- getable synthetic lethality in cohesin-mutant cancers. Nat Commun. 2019;10(1):1686.
32. Meisenberg C, Pinder SI, Hopkins SR, et al. repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. Mol Cell. 2019; 73(2):212-223.e7.
33. Kuendgen A, Muller-Thomas C, Lauseker M, et al. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a
review of the literature. Oncotarget. 2018;
9(45):27882-27894.
34.Polgarova K, Vargova K, Kulvait V, et al.
Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selec- tion in patients-responders. Oncotarget. 2017;8(67):111966-111978.
35. Tobiasson M, McLornan DP, Karimi M, et al. Mutations in histone modulators are associ- ated with prolonged survival during azaciti- dine therapy. Oncotarget. 2016;7(16):22103- 22115.
36. Cabezon M, Bargay J, Xicoy B, et al. Impact
of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget. 2018;9(27):19342-19355.
37.Dohner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018; 32(12):2546-2557.
haematologica | 2021; 106(8)
2223